Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2005-6-27
pubmed:abstractText
The prevalence of epilepsy is about 1%. Only two thirds of these patients respond satisfactorily to an antiepileptic drug (AED) treatment. New AED did not clearly improve this overall efficacy, but often show a better tolerability as compared to old AED. This may allow a more targeted choice, especially in some delicate clinical situations, such as for the treatment of women in childbearing age, or patients receiving other drugs with possible pharmacokinetic interactions. Invasive approaches should be considered early in the course of treatment-resistant epilepsy, and may offer a complete seizure remission in selected cases. On the background of recent acquisitions from the literature, the pros and cons of different treatment options are presented. This is followed by the discussion of some clinical relevant situations.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1660-9379
pubmed:author
pubmed:issnType
Print
pubmed:day
4
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1220, 1222, 1224-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[Current epilepsy treatment in adults].
pubmed:affiliation
Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. arossetti@partners.org
pubmed:publicationType
Journal Article, English Abstract, Review, Research Support, Non-U.S. Gov't